Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Serum_Institute_of_India
gptkb:Rubella_vaccine |
| gptkbp:age |
12 to 15 months
|
| gptkbp:appointed_by |
gptkb:Person
|
| gptkbp:associated_with |
herd immunity
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:clinical_trial |
extensively studied
|
| gptkbp:contraindication |
immunocompromised individuals
severe allergic reaction |
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
4 to 6 years
two doses |
| gptkbp:first_introduced |
gptkb:1971
|
| gptkbp:formulation |
live attenuated virus
|
| gptkbp:global_presence |
widely used worldwide
|
| gptkbp:has_lore |
contains mercury
causes autism is not safe |
| gptkbp:healthcare |
reduction in disease incidence
|
| https://www.w3.org/2000/01/rdf-schema#label |
MMR vaccine
|
| gptkbp:is_effective_against |
approximately 88% for rubella
approximately 97% for measles approximately 78% for mumps |
| gptkbp:is_vulnerable_to |
varies by region
updated periodically varies by country public health programs ongoing studies part of vaccination campaigns monitored by health organizations combination vaccine part of childhood vaccination schedule important for parents VAERS system common concern significantly reduced outbreaks |
| gptkbp:manager |
subcutaneous
|
| gptkbp:public_awareness |
critical for public health
|
| gptkbp:regulatory_compliance |
FDA approved
EMA approved |
| gptkbp:side_effect |
fever
rash anaphylaxis thrombocytopenia swelling of glands febrile seizures |
| gptkbp:suitable_for |
gptkb:CDC
gptkb:WHO |
| gptkbp:targets |
gptkb:rubella
gptkb:measles mumps |